Sign up for the QMED & MD+DI Daily newsletter.
February 8, 2023
2 Min Read
Image credit: Peter Dazeley / The Image Bank via Getty Images
London, England-based Huma Therapeutics and Bayer have teamed up to develp an online tool where people can check their risk of getting heart disease.
The tool does not replace a physician's assessment, the companies caution, but the 15-question assessment may determine if an individual is at a higher, average, or lower risk for developing heart disease. Huma developed the algorithm using data from the UK's Biobank which predicts long-term heart disease risk, and the research has been validated and published in the European Heart Journal Digital Health.
"We are tremendously excited to have the opportunity to scale our evidence-based digital innovations to advance personalized health tools like the Bayer Aspirin Risk Assessment for populations around the world. We are honored to have earned the trust of one of the world's largest life sciences companies to collaborate with on this pioneering initiative," said Huma Founder and CEO Dan Vahdat. "We see ourselves as part of a global movement to bring digital technology to healthcare and research and improve health outcomes for people everywhere."
Bayer plans to launch a national public awareness campaign in the United States about ongoing heart health education and heart disease risk management that will use the new online tool as a core pillar. The campaign will aim to encourage those at elevated risk to talk to their healthcare professional about their risk profile as a proactive way to manage their health risks.
"Bayer is committed to providing the public with quality healthcare solutions and is pleased to provide a cutting-edge educational resource that can effectively shape heart health conversations with anyone at risk and their physician," said Reese Fitzpatrick, senior vice president and global marketing head at Bayer. "We are excited to partner with Huma and to leverage its pioneering digital assessment tool to help people get meaningful insights on their health in an accessible and direct way."
About the Author(s)
You May Also Like
Masimo Takes Apple's Hail Mary Pass in StrideFeb 29, 2024|3 Min Read
Top 40 Medical Device CompaniesFeb 29, 2024|2 Min Read
2024 Planning Guide for Medical Manufacturing AutomationFeb 29, 2024|1 Min Read
Adverse Events Reported for Hologic BioZorb Marker, BioZorb LP MarkerFeb 28, 2024|2 Min Read